|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rare and treatable variant of CAA likely due to an autoimmune response directed toward beta-amyloid deposits.
|
31715460 |
2020 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A nationwide survey was conducted to understand the epidemiology of cerebral amyloid angiopathy-related intracerebral hemorrhage (CAA-related ICH) and cerebral amyloid angiopathy-related inflammation/vasculitis (CAA-ri) in Japan.
|
31232495 |
2019 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background and Purpose- Hematoma location within the cerebellum may help identify the dominant small vessel disease type (cerebral amyloid angiopathy [CAA] versus nonamyloid small vessel disease).
|
31159702 |
2019 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Background Cerebral amyloid angiopathy ( CAA ) is a major cause of lobar intracerebral hemorrhage in elderly adults; however, presymptomatic diagnosis of CAA is difficult.
|
30717612 |
2019 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
CADASIL, CARASIL, Trex1-related microangiopathies, CARASAL, familial forms of cerebral amyloid angiopathy or CAA) have provided interesting cellular and molecular clues to the pathogenesis of sporadic microvascular disease such as arteriolosclerosis and AD-related CAA.
|
29380913 |
2018 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cerebral amyloid angiopathy-related inflammation (CAA-ri) is associated with a cerebrospinal fluid (CSF) biomarker profile similar to that observed in CAA.
|
29254099 |
2018 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amyloid-β deposition in the microvasculature of the brain, a process referred to as capillary cerebral amyloid angiopathy (capillary CAA), propagates vascular remodelling, which results in impaired function of the blood-brain barrier, reduced cerebral perfusion and increased hypoxia.
|
30462206 |
2018 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We estimated annualized recurrent symptomatic ICH rates for each study and compared pooled odds ratios (ORs) of recurrent ICH by CMB presence/absence and presumed etiology based on CMB distribution (strictly lobar CMBs related to probable or possible cerebral amyloid angiopathy [CAA] vs non-CAA) and burden (1, 2-4, 5-10, and >10 CMBs), using random effects models.
|
28747441 |
2017 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brain magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) sometimes reveals multiple cerebral microbleeds (CMBs) and confluent white matter hyperintensities (WMHs) similar to those observed in cerebral amyloid angiopathy-related inflammation (CAA-I).
|
28000005 |
2017 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that vascular amyloid contributes to chronic brain ischemia, therefore amyloid burden measured by Pittsburgh compound B retention on positron emission tomography (PiB PET) would correlate with the extent of magnetic resonance imaging (MRI) white matter hyperintensities (WMH; or leukoaraiosis) in patients with high vascular amyloid deposition (cerebral amyloid angiopathy [CAA]) but not in patients with high parenchymal amyloid deposition (Alzheimer disease [AD]; mild cognitive impairment [MCI]) or in healthy elderly (HE) subjects.
|
23424091 |
2013 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immune response to vascular amyloid-β deposits leads to cerebral amyloid angiopathy related-inflammation (CAA-ri).
|
23948920 |
2013 |
|
Cerebral Amyloid Angiopathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective clinico-pathologic study of 100 patients with autopsy proven PD (including 44 cases with dementia/PDD) and 20 cases of dementia with Lewy bodies (DLB) confirmed essential clinical (duration of illness, Mini-Mental State Examination/MMSE, age at death) and morphologic differences between these groups; Lewy body Braak scores and Alzheimer pathologies (neuritic Braak stage, cortical Abeta plaque load, and generalized cerebral amyloid angiopathy or CAA) were significantly higher/more severe in DLB and PDD than in PD without dementia.
|
18273624 |
2008 |